Pfizer Stock News

Markets were scared to wake up to the Federal Reserve (the Fed) pulling the rug. After pricing in the proposed interest rate cuts for 2024, which were set to be implemented by March, then May, and now

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline

A financial advisor can help you understand the advantages and disadvantages of investment properties.

In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks. These prospects result from i

Big money tends to flow from one sector to the other. During the pandemic, sectors like pharmaceutical and e-commerce were hot.

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Vikin

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.

Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.

It's an established point that blue-chip stocks are an essential part of the portfolio. The exposure to blue-chips can differ based on the risk-taking ability of an investor.

Enterprise Products Partners offers an ultra-high distribution yield plus solid growth prospects. Intel could roar back with a massive AI tailwind.

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Take the quiz below to get matched with a financial advisor today. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sa

Today, I will present you with two attractive high dividend yield companies that can help to enhance your dividend income. I have added both companies to The Dividend Income Accelerator Portfolio. Thi